

SEQUENT RECEIVES US FDA APPROVAL FOR ITS API DRUG MANUFACTURING FACILITY AT MANGALORE

April 30, 2013; Bangalore: SeQuent Scientific Limited (SeQuent) today announced that it has received an US FDA approval for its API Drug Manufacturing facility at Mangalore, Karnataka (SeQuent Mangalore). This facility has earlier received quality approval from TGA, Australia and certified by World Health Organisation, Geneva under its Prequalification's of Medicines Programme.

The SeQuent Mangalore facility is ISO 9001 certified for Quality Management systems and ISO 14000 certified for Environment Management systems. This state-of-the-art facility engaged in the development and manufacture of APIs and API Intermediaries.

Commenting on this milestone, Dr. Gautam Kumar Das, Executive Director, said, "The US FDA approval endorses our commitment to ensure strong regulatory compliance as well as our dedication to offer quality products through research. Being the first ever for the company, this approval will further rejuvenate us in establishing SeQuent among the finest global API Manufacturers".

SeQuent Mangalore specializes in niche and difficult to manufacture APIs and has 5 of its APIs prequalified by WHO Prequalification of Medicines program. It has filed more than 30 drug master files covering USFDA, Europe, WHO, Australia, Canada with several more niche APIs in the pipeline for future filings.

About SeQuent Scientific Limited

SeQuent Scientific Limited, listed on the Bombay Stock Exchange Limited (stock code: 512529) is an integrated pharmaceutical company with a global footprint headquartered in Bangalore, India which has presence in different pharmaceutical verticals including APIs, Animal Health, Analytical Services, CRAMS and specialty chemicals. SeQuent is the world's largest producer of Anthelmintics and by far the strongest player in the Veterinary API business.

SeQuent's manufacturing sites located across India are equipped to handle a wide range of reactions in synthetic chemistry, fermentation and extraction. Presently the company has 7 manufacturing facilities. All facilities adhere to strict global quality standards.

Manufacturing is ably supported by state-of-the-art R&D centre located in Mangalore, which is recognized by DSIR, Government of India.

Additional information is available at the company's website at www.sequent.in

For further information, please contact:

Mr. PR Kannan, CFO, SeQuent Scientific Limited
+91 80 6784 0327; kannan.pr@sequent.in

Mr. Rohit Yagnik, Fortuna PR
+91 98338 07272; rohit@fortunapr.in